Skip to main content
SpringerLink
Log in

Collagenase Clostridium histolyticum in Peyronie’s disease: a guide to its use in the EU

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Collagenase Clostridium histolyticum (CCH; Xiapex®; Xiaflex®) intralesional injection is indicated for the treatment of adult men with Peyronie’s disease with a palpable plaque and curvature deformity of ≥30° at the start of therapy. In clinical trials, CCH significantly improved penile curvature deformity and reduced patient-reported bother associated with Peyronie’s disease. It is generally well tolerated, with most treatment-related adverse events being of mild or moderate severity. Serious treatment-related adverse events (penile haematoma or corporal ruptures) were reported in <1 % of CCH recipients in clinical studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Alwaal A, Hussein AA, Zaid UB, et al. Management of Peyronie’s disease after collagenase (Xiaflex®). Curr Drug Targets. 2014;16(5):484–94.

    Article  Google Scholar 

  2. Egui Rojo MA, Moncada Iribarren I, Carballido Rodriguez J, et al. Experience in the use of collagenase clostridium histolyticum in the management of Peyronie’s disease: current data and future prospects. Ther Adv Urol. 2014;6(5):192–7.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Moreland RB, Nehra A. Pathophysiology of Peyronie’s disease. Int J Impot Res. 2002;14(5):406–10.

    Article  CAS  PubMed  Google Scholar 

  4. Rosen R, Catania J, Lue T, et al. Impact of Peyronie’s disease on sexual and psychosocial functioning: qualitative findings in patients and controls. J Sex Med. 2008;5(8):1977–84.

    Article  PubMed  Google Scholar 

  5. Dibenedetti DB, Nguyen D, Zografos L, et al. A population-based study of Peyronie’s disease: prevalence and treatment patterns in the United States. Adv Urol. 2011;2011:282503.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Sommer F, Schwarzer U, Wassmer G, et al. Epidemiology of Peyronie’s disease. Int J Impot Res. 2002;14(5):379–83.

    Article  CAS  PubMed  Google Scholar 

  7. Hatzimouratidis K, Giuliano EF, Moncada I, et al. Guidelines on penile curvature. Arnhem: European Association of Urology; 2015.

    Google Scholar 

  8. Xiapex (collagenase Clostridium histolyticum): summary of product characteristics. London: European Medicines Agency; 2016.

  9. Xiaflex (collagenase clostridium histolyticum): US prescribing information. Malvern: Auxilium Pharmaceuticals Inc.; 2015.

  10. Levine LA, Schmid TM, Emeigh Hart SG, et al. Collagenase Clostridium histolyticum degrades type I and III collagen while sparing type IV collagen in vitro in Peyronie’s plaque explants [abstract no. PD22-03 plus oral presentation]. In: American Urological Association Annual Meeting. 2014.

  11. Gelbard MK, Walsh R, Kaufman JJ. Collagenase for Peyronie’s disease experimental studies. Urol Res. 1982;10(3):135–40.

    Article  CAS  PubMed  Google Scholar 

  12. Del Carlo M, Cole AA, Emeigh Hart SG, et al. Comparative analaysis of collagen degradation in Peyronie’s disease plaque and Dupuytren’s contracture cord tissue injected with mixed collagenase subtypes [abstract no. 780]. J Urol. 2009;181(4 Suppl):279.

    Article  Google Scholar 

  13. Gelbard MK, Lindner A, Kaufman JJ. The use of collagenase in the treatment of Peyronie’s disease. J Urol. 1985;134(2):280–3.

    CAS  PubMed  Google Scholar 

  14. Gelbard MK, James K, Riach P, et al. Collagenase versus placebo in the treatment of Peyronie’s disease: a double-blind study. J Urol. 1993;149(1):56–8.

    CAS  PubMed  Google Scholar 

  15. Jordan GH. The use of intralesional Clostridial collagenase injection therapy for Peyronie’s disease: a prospective, single-center, non-placebo-controlled study. J Sex Med. 2008;5(1):180–7.

    Article  PubMed  Google Scholar 

  16. Gelbard M, Lipshultz LI, Tursi J, et al. Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease. J Urol. 2012;187(6):2268–74.

    Article  CAS  PubMed  Google Scholar 

  17. McKeage K, Lyseng-Williamson KA. Collagenase Clostridium histolyticum in Dupuytren’s contracture: a guide to its use in the EU. Drugs Ther Perspect. 2016;32(4):131–7.

    Article  Google Scholar 

  18. Gelbard M, Goldstein I, Hellstrom WJ, et al. Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190(1):199–207.

    Article  CAS  PubMed  Google Scholar 

  19. Gelbard M, Hellstrom WJ, McMahon CG, et al. Baseline characteristics from an ongoing phase 3 study of collagenase Clostridium histolyticum in patients with Peyronie’s disease. J Sex Med. 2013;10(11):2822–31.

    Article  PubMed  Google Scholar 

  20. McMahon C, Auerbach S, Liu G, et al. Curvature deformity and symptom bother improvement over time in patients with Peyronie’s disease treated with collagenase Clostridium histolyticum [abstract no. 1661]. In: 108th Annual Meeting of the American Urological Association. 2013.

  21. Assessment report (Xiapex). London: European Medicines Agency; 2014.

  22. Hellstrom WJ, Feldman R, Rosen RC, et al. Bother and distress associated with Peyronie’s disease: validation of the Peyronie’s disease questionnaire. J Urol. 2013;190(2):627–34.

    Article  PubMed  Google Scholar 

  23. Coyne KS, Currie BM, Thompson CL, et al. Responsiveness of the Peyronie’s Disease Questionnaire (PDQ). J Sex Med. 2015;12(4):1072–9.

    Article  PubMed  Google Scholar 

  24. Lipshultz LI, Goldstein I, Seftel AD, et al. Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie’s disease by subgroups: results from two large, double-blind, randomized, placebo-controlled, phase 3 studies. BJU Int. 2015;116(4):650–6.

    Article  CAS  PubMed  Google Scholar 

  25. Levine LA, Cuzin B, Mark S, et al. Clinical safety and effectiveness of collagenase Clostridium histolyticum injection in patients with Peyronie’s disease: a phase 3 open-label study. J Sex Med. 2015;12(1):248–58.

    Article  PubMed  Google Scholar 

  26. Goldstein I, Knoll D, Lipshultz LI, et al. Changes in the effects of Peyronie’s disease after treatment with collagenase Clostridium histolyticum according to men with Peyronie’s disease and their female sexual partners [abstract no. 064]. In: 20th Annual Fall Scientific Meeting of SMSNA. 2014.

  27. Ziegelmann MJ, Viers BR, McAlvany KL, et al. Restoration of penile function and patient satisfaction with intralesional collagenase Clostridium histolyticum injection for Peyronie’s disease. J Urol. 2016;195(4P1):1051–6.

    Article  PubMed  Google Scholar 

  28. Carson CC, Sadeghi-Nejad H, Tursi JP, et al. Analysis of the clinical safety of intralesional injection of collagenase Clostridium histolyticum for adults with Peyronie’s disease. BJU Int. 2015;116(5):815–22.

    Article  CAS  PubMed  Google Scholar 

  29. Levine LA, Larsen SM. Surgical correction of persistent Peyronie’s disease following collagenase clostridium histolyticum treatment. J Sex Med. 2015;12(1):259–64.

    Article  PubMed  Google Scholar 

  30. Nehra A, Alterowitz R, Culkin DJ, et al. Peyronie’s disease: AUA guideline. Linthicum: American Urological Association Education and Research, Inc; 2015.

    Google Scholar 

  31. Dhillon S. Collagenase Clostridium histolyticum: a review in Peyronie’s disease. Drugs. 2015;75(12):1405–12.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The review was updated from Drugs 2015;75(12):1405–12 [31], and was reviewed by: M. Bozlu, University of Mersin School of Medicine, Mersin, Turkey; W. J. G. Hellstrom and F. A. Yafi, Tulane University School of Medicine, New Orleans, LA, USA. During the peer review process, the manufacturer of Xiapex® was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Sohita Dhillon

Authors
  1. Sohita Dhillon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sohita Dhillon.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

S. Dhillon is a salaried employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dhillon, S. Collagenase Clostridium histolyticum in Peyronie’s disease: a guide to its use in the EU. Drugs Ther Perspect 32, 311–316 (2016). https://doi.org/10.1007/s40267-016-0318-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-016-0318-1

Keywords

Search

Navigation